---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-018819"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-05-29T13:26:14+00:00"
generated_at: "2026-05-29T13:27:23.070826+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moleculin ASCO data: Annamycin shows no cardiotoxicity at high cumulative doses

## Summary
- Pooled analysis of 90 patients: no significant LVEF change (mean diff -0.12%, p=0.84) across doses up to 2,970 mg/m².
- Independent Cleveland Clinic review confirms no drug-induced cardiotoxicity across ECGs, biomarkers, and adverse events.
- Phase 1b/2 AML study achieved 50% CR, 60% CRc, median overall survival 12.39 months; 50% of responders received transplant.
- Pivotal Phase 2b/3 MIRACLE trial unblinding of first 45 patients on track for June 2026.

## SEC filing metadata
- accession: 0001437749-26-018819
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-05-29T13:26:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926018819/0001437749-26-018819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926018819/mbrx20260529_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-018819
- JSON: https://secwatch.observer/filing/0001437749-26-018819.json
- Plain text: https://secwatch.observer/filing/0001437749-26-018819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.